Nowicka J, Kuliszkiewicz-Janus M, Fischer W
Kliniki Hematologii AM we Wrocławiu.
Pol Tyg Lek. 1990;45(51-52):1042-5.
Livex is a lyophilised preparation of the bovine blood which contains 70% of proteins and 0.3% of iron. Livex was given to 25 patients with iron deficiency anemia (group I), and 25 patients with lymphoreticular malignancies accompanied by iron deficiency with or without anemia. The dose was 5 g t.i.d. for 3 months. The majority of patients of group I were women. Excessive menstrual bleeding and chronic gastritis were most common causes of iron deficiency in this group. Livex statistically significantly increased hemoglobin, hematocrit, corrected reticulocyte count, mean erythrocyte hemoglobin, serum iron, percent transferrin saturation, and leukocyte count. Therapy produced significant increase in serum iron, total iron binding capacity, and percent transferrin saturation in patients with lymphoreticular malignancies.
利维克斯是一种冻干的牛血制剂,含有70%的蛋白质和0.3%的铁。将利维克斯给予25例缺铁性贫血患者(第一组),以及25例伴有缺铁且有或无贫血的淋巴网状恶性肿瘤患者。剂量为每日3次,每次5克,持续3个月。第一组的大多数患者为女性。月经过多和慢性胃炎是该组缺铁的最常见原因。利维克斯在统计学上显著提高了血红蛋白、血细胞比容、校正网织红细胞计数、平均红细胞血红蛋白、血清铁、转铁蛋白饱和度百分比和白细胞计数。该疗法使淋巴网状恶性肿瘤患者的血清铁、总铁结合力和转铁蛋白饱和度百分比显著增加。